Abstract LB-230: A prospective clinical trial to evaluate DNA sequencing as a diagnostic tool to guide cancer therapy: results from the initial 50 patients

摘要: Background:We are conducting a multicenter clinical trial to evaluate the feasibility of including next-generation sequencing in routine care. Study goals determine patient acceptance research biopsies for genomic sequencing, optimal methods and procedures sample collection, DNA extraction successful analysis, review reporting mutations back clinicians patients with three weeks. Methods: Patients (pts) metastatic cancer potentially eligible trials recruited from 4 centers. A tumor biopsy, blood archived specimens collected consenting patients. samples analyzed using Pacific Biosciences RS targeted gene Sequenom Oncocarta™ V1.0 genotyping. Detected validated CAP/CLIA certified laboratory. An expert panel scientists results whether actionable reportable clinicians. Results: As 01/2012, 50 pts have been recruited. Pt demographics include median age = 57; primary colorectal 9 (18%), breast 8 (16%), ovary lung 5 (10%), others 20 (40%); number prior treatments 3; time disease 17 months. Over 90% approached consented study. Molecular profiling by was 43 (86%) 100% concordance between platforms. Somatic were identified over 30% pts; 75% these (including KRAS, PIK3CA, EGFR, RET, KIT) deemed actionable. Seven (14%) had treatment impacted matching therapy genetic profile; benefit (1 PR ovarian cancer, 1 SD 2 benefits thyroid unknown squamous cell cancers). Four novel AKT1, PDGFRA, EGFR KRAS not present on Oncocarta demonstrating added entire exon. Genomic fresh matched 26 30 (90%) paired samples. 62% delivery report within Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings 103rd Annual Meeting American Association Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Res 2012;72(8 Suppl):Abstract nr LB-230. doi:1538-7445.AM2012-LB-230